Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (1469)	2/4/1998 8:01:00 PM
From: Gregory Rasp	Read Replies (1) \| Respond to of 1762

I am very familiar with the trial. Actually there are two randomized trials that both showed a survival benefit with the addition of radiation to CHOP. The other is the ECOG trial published in abstract form with the first author Glick. I'll bring both home from work tomorrow. Since I am a radiation oncologist I found your last comment a little disconcerting. No radiation means Greg hits the unemployment line. Seriously though radiation is (in my opinion) much more precise and much safer than CHOP. Radiation is at least aimed at the source of the problem. I know that it is not intuitively obvious but radiation is far superior to surgery for the treatment of localized lymphomas. CHOP on the other hand is quite toxic. C - Cytoxan (alkylating agent that can cause acute leukemia in a dose dependent fashion). H - Adriamycin (heart toxin also dose dependent) O - Vincristine (neurotoxin with high incidence of peripheral neuropathies) P - Prednisone (not a particular problem) SO, when you can substitute 20-40Gy for a few cycles of chemotherapy, you usually win in terms of toxicity. Greg